Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,611.83
(
0.44%
)
US TECH 100
23,538.00
(
0.59%
)
Dow Jones
46,669.88
(
0.36%
)
Brent Oil
107.07
(
-1.93%
)
Bitcoin
69,465.39
(
0.66%
)
News Focus
News Focus
Post# of 57672
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

K-G

Send PM Follow Ignore
Followers 4
Posts 153
Boards Moderated 0
Alias Born 10/25/2006

K-G

Re: Aiming4 post# 1702

Thursday, 10/26/2006 5:45:03 PM

Thursday, October 26, 2006 5:45:03 PM

Post# of 57672
Aiming4,
If I read between the lines correctly, Dr. Stoll expects that if there are no additional issues found with CX-717, and the toxicology assessments show a suitable safe dosing range, then they would conduct some TBD AD efficacy tests, the results of which would be available mid-year 2007 at the earliest. He also said he does not expect any AD deals to be made in the absence of solid efficacy data.
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today